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Background:  Hypertension and type 2 diabetes mellitus are major risk factors for cardiovascular disease. This study analyzed 
the changes in central aortic waveforms and pulse wave velocity as well as related parameters after treatment with valsartan, an 
angiotensin II type 1 receptor blocker, in patients with type 2 diabetes and hypertension.
Methods:  We used pulse wave analysis to measure central aortic waveform in a total of 98 subjects. In 47 of these patients, pulse 
wave velocity measurements were obtained before and after 12 weeks of treatment with valsartan. 
Results:  In the central aortic waveform analysis, the aortic pulse pressure and augmentation index were significantly decreased 
after valsartan treatment, as was the aortic pulse wave velocity. Factors contributing to the improvement in pulse wave velocity 
were the fasting blood glucose and haemoglobin A1c levels. 
Conclusion:  Short-term treatment with valsartan improves arterial stiffness in patients with type 2 diabetes and hypertension, 
and the glucose status at baseline was associated with this effect. 
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INTRODUCTION 
Cardiovascular disease (CVD) is the largest cause of morbidity 
and mortality in patients with type 2 diabetes mellitus (T2DM) 
[1]. Hypertension is a common comorbidity in patients with 
T2DM, and these two diseases are major risk factors for CVD 
[2]. In T2DM, hypertension often initiates and accelerates the 
progression of macrovascular events by increasing arterial 
stiffness, which results in the aggravation of ventricular after-
load and the impairment of coronary perfusion [3,4]. Increased 
arterial stiffness was recently reported to be a powerful and in-
dependent risk factor for early mortality, and presented more 
clinical prognostic value than previously known CVD risk fac-
tors such as age, gender, smoking, and dyslipidemia [5]. There-
fore, the measurement of arterial stiffness and the control of 
other risk factors would be important strategies for the pre-
vention and early treatment of cardiovascular events.
  Angiotensin II receptor blockers (ARBs) have been shown 
to have a beneficial effect on angiopathy resulting from hyper-
tension and impaired glucose metabolism. ARBs are regarded 
as first-line treatment for T2DM with hypertension and some 
studies have reported an effect of the blockade of the renin-
angiotensin-aldosterone system (RAAS) on arterial stiffness in 
T2DM and hypertension [6-8]. However, the effect of ARBs 
on arterial stiffness, as well as the mechanism and related fac-
tors, are poorly understood in T2DM with hypertension. Val-
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sartan is an angiotensin II type 1 (AT1) receptor blocker that 
has antihypertensive effects. To examine the effect of the ARB 
valsartan on arterial stiffness and related parameters in T2DM 
with hypertension, we analyzed the changes in central aortic 
waveforms and aortic pulse wave velocity (PWV) after treat-
ment with valsartan for 12 weeks.
METHODS 
Research setting and study population
Our study population included patients between 30 and 75 
years of age who had T2DM and who visited one of three cen-
ters from February 2006 to February 2008. Patients with a 
<10-year recorded history of T2DM diagnosed according to 
the American Diabetes Association criteria, a verified body 
mass index (BMI) between 20 and 30 kg/m
2, and a verified 
Hemoglobin A1c (HbA1c) level between 6.5% and 10% were 
eligible for this study. Eligibility criteria also included mild to 
moderate hypertension as defined by the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure, i.e., brachial systolic blood pressure (SBP) 
of 140 to 160 mm Hg and diastolic blood pressure (DBP) of 90 
to 100 mm Hg. Exclusion criteria included a history of isch-
emic heart disease in the preceding 3 months, biochemical ev-
idence of renal impairment (creatinine >1.5 mg/dL), liver en-
zyme levels more than three times the normal limits, and preg-
nancy or nursing at the time of the study. Additional exclusion 
criteria included the concomitant use of medications such as 
ACE inhibitors or other ARBs at entry and the use of insulin 
or antidiabetic drugs such as thiazolidinedione or metformin 
in the preceding 3 months. A total of 107 Korean subjects were 
recruited for this study. After nine subjects withdrew, 98 sub-
jects (41 men and 57 women) were available for analysis.
Study design
This study was a multi-centre, open label, controlled study to 
investigate the short-term effect of a 12-week treatment with 
valsartan on arterial stiffness in T2DM with hypertension. Pa-
tients receiving other antihypertensive agents for systolic hyper-
tension were permitted to enter the trial after a 2-week wash-
out of the drug and hypertension was controlled by valsartan 
thereafter. Arterial blood pressure was measured in the right 
arm using a mercury sphygmomanometer, three times under 
resting conditions in the morning by a selected physician, and 
the mean values were calculated for this study. All study sub-
jects underwent anthropometric measurements, including 
height, weight, and BMI, as well as blood chemistry analysis, 
including fasting blood glucose, HbA1c, insulin, BUN, creati-
nine, and uric acid levels; liver function tests; and lipid pro-
files. An estimate of insulin resistance was obtained by homeo-
stasis model assessment of insulin resistance (HOMA-IR), 
which was calculated using the following formula: fasting in-
sulin (mU/L)×fasting glucose (mmol/L)/22.5. The central 
aortic waveform was measured using pulse wave analysis by 
applanation tonometry (Sphygmocor; AtCor Medical Inc., 
Sydney, Australia) in all study subjects, and aortic PWV mea-
surements were taken in 47 of the study subjects.
  After the screening examination, all participants received 
an initial daily dose of 80 mg of valsartan. After 4 weeks, the 
valsartan dose was increased to 160 mg/day for 8 weeks. All 
subjects were advised to consume their usual diet and medica-
tions other than valsartan were not changed during the study. 
Basic assessment, blood sampling, and central aortic waveform 
measurement were evaluated before and after the 12-week ad-
ministration. Aortic PWV was measured in 47 randomly se-
lected among subjects who measured pulse wave analysis 
(PWA). To evaluate the factors contributing to the improve-
ment of PWV with valsartan administration, these patients 
were divided into two groups: one group in which PWV de-
creased and the other in which PWV did not decrease. The 
Ethics Committee of each hospital approved this study proto-
col, and informed consent was obtained from all subjects. 
Measurement of arterial stiffness 
Central aortic waveform measurements were made using pulse 
wave analysis by applanation tonometry (Sphygmocor). Radi-
al artery pressure waveforms were obtained from the wrist us-
ing a tonometer, and a corresponding central waveform was 
generated with a validated generalized transfer function, using 
the Sphygmocor. The Sphygmocor generates ascending aortic 
pressure waveforms from the radial pulse and provides sub-
stantially equivalent values of aortic systolic, pulse, mean, and 
diastolic pressures [9]. The integrated Sphygmocor software 
was used to determine the augmentation index (AIx), which is 
a composite measure of systemic arterial stiffness and wave-
reflection amplitude, as well as the ejection duration (ED) and 
subendocardial viability ratio (SEVR). The aortic (carotid to 
femoral) PWV and relevant transient times were measured 
noninvasively by tonometry, using the Sphygmocor system as 
mentioned above. For each subject, the distance travelled by 238
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the pulse wave between the carotid-femoral arteries was mea-
sured in a straight line. The investigators who performed the 
measurements had been fully trained in the technique of ap-
planation tonometry. The precision of the method was deter-
mined by the interobserver and intraobserver variabilities, 
which were 0.93 and 0.95, respectively, for AIx and 0.9 and 0.9 
for PWV.
Statistical analysis
Treatment-related changes in parameters were analyzed using 
a Wilcoxon test. We analyzed the relationship between the 
change in arterial stiffness and changes in other parameters 
using Spearman’s correlation test. Continuous values are ex-
pressed as means±standard deviation (SD). A P value of less 
than 0.05 was considered statistically significant. Statistical 
analysis was performed using SPSS version 10.0 (SPSS Inc., 
Chicago, IL, USA). 
RESULTS 
A total of 98 (41 men and 57 women) patients were eligible for 
analysis in the study. The demographic characteristics of the 
patients and the alterations in their clinical and laboratory pa-
rameters are shown in Table 1. In the central aortic waveform 
analysis, aortic pulse pressure (44.4±8.5 vs. 38.9±10.2 mm Hg, 
P<0.05) and AIx (29.5±7.4% vs. 27.8±7.9%, P<0.05) were 
significantly decreased after valsartan treatment without in-
crease of heart rate. However, the SEVR and ED did not change 
significantly (Table 2). At the end of the 12-week treatment, 
there were significant decreases in SBP (148.6±5.7 vs. 132.3± 
13.0 mm Hg, P<0.001) and DBP (91.4±2.7 vs. 81.2±10.1 mm 
Hg, P<0.001) (Table 3). There were no observed changes in 
the levels of total cholesterol, triglycerides, low density lipo-
Table 1. Baseline characteristics of the study subjects
Variable
All subjects 
(n=98)
Subjects of PWV  
estimation (n=47)
Sex, M/F 41/57 24/23
Age, yr 58.4±7.9 58.0±7.5
DM duration, yr 5.2±3.0 4.5±3.4
BMI, kg/m
2 25.4±2.5 25.6±2.4
SBP, mm Hg 148.6±5.7 148.1±6.0
DBP, mm Hg 91.4±2.7 91.5±3.1
Fasting blood glucose, 
mmol/L
7.9±2.1 8.1±2.1
HbA1c , % 7.5±1.1 7.5±1.2
HOMA IR 2.2±1.8 2.7±1.9
Total cholesterol, mmol/L 4.7±1.0 4.8±0.9
HDL-C, mmol/L 1.4±0.9 1.2±0.4
Triglyceride, mmol/L 1.7±1.1 1.9±1.2
LDL-C, mmol/L 2.7±0.9 2.7±0.7
Continuous parameters are presented as mean±standard deviation. 
PWV, pulse wave velocity; DM, diabetes mellitus; BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HbA1c, haemoglobin A1c; HDL-C, high density lipoprotein choles-
terol; HOMA IR, homeostasis model assessment of insulin resistance; 
LDL-C, low density lipoprotein cholesterol.
Table 2. Changes in central hemodynamic parameters and 
PWV from baseline to week 12 
Sphygmocor parameter Baseline  
value
Week 12  
value P value
Heart rate, bpm 71.3±11.4 69.7±10.8 0.054
Aortic augmentation index, %  29.5±7.4 27.8±7.9 <0.05
Aortic pulse pressure, mm Hg  44.4±8.5 38.9±10.2 <0.001
Subendocardial viability ratio  144.5±26.3 147.9±28.1 0.060
Ejection duration, msec  372.0±74.0 368.0±41.0 0.092
PWV, m/sec (n=47) 10.9±1.1 10.0±1.2  <0.05
Continuous parameters are presented as mean±standard deviation. 
PWV, pulse wave velocity.
Table 3. Change in anthropometric parameters after valsartan 
treatment
Parameter Baseline value Week 12 value  P value
BMI, kg/m
2  25.4±2.5 25.6±2.8 0.388
SBP, mm Hg  148.6±5.7 132.4±13.0 <0.001
DBP, mm Hg  91.4±2.7 81.2±10.1 <0.001
Fasting blood glucose,  
mmol/L 
7.93±2.08 7.95±1.97 0.714
HbA1c, %  7.5±1.1 7.4±1.5 0.239
HOMA-IR 2.2±1.8 2.0±1.3 0.315
Total cholesterol, mmol/L  4.74±1.04 4.76±0.95 0.879
HDL-C, mmol/L 1.40±0.86 1.33±0.31 0.969
Triglyceride, mmol/L 1.70±1.10 1.70±0.89 0.478
LDL-C, mmol/L 2.72±0.85 2.77±31.0 0.492
Continuous parameters are presented as mean±standard deviation.   
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; HbA1c, haemoglobin A1c; HDL-C, high density li-
poprotein cholesterol; HOMA IR, homeostasis model assessment of 
insulin resistance; LDL-C, low density lipoprotein cholesterol.239
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protein cholesterol, high density lipoprotein cholesterol, fast-
ing glucose, HbA1c, and HOMA-IR (Table 3). The change in 
SBP correlated only with the decreases in AIx (P<0.01) and 
aortic pulse pressure (P<0.01) (data not shown). 
  In a subgroup analysis of the 47 patients with measured PWV, 
the mean aortic PWV was significantly decreased (10.9±1.1 
vs. 10.0±1.2 m/sec, P<0.05) without a change in heart rate af-
ter valsartan treatment (Table 2). Among the baseline parame-
ters, there were significant differences in the levels of fasting 
blood glucose (138.2±34.7 vs. 163.7±39.9 mg/dL) and HbA1c 
(7.1±1.0% vs. 8.6±1.1%) between the two groups (P<0.05). 
The change in mean arterial pressure was not different between 
the two groups.
  In logistic regression analysis, HbA1c was the only indepen-
dent factor associated with aortic PWV improvement (hazard 
ratio, 2.638; P<0.05) (Table 4). Patients with improved PWV 
presented significantly better blood glucose levels at baseline 
compared to those with no PWV improvement. 
DISCUSSION 
Hypertension and T2DM are major risk factors for cardiovas-
cular disease, and the degree of atherosclerosis can be deter-
mined by measuring arterial stiffness. The detection of arterial 
stiffness and the control of risk factors are becoming impor-
tant strategies in the prevention and early treatment of cardio-
vascular events. Arterial stiffness can be assessed by the sim-
ple, validated, and reproducible technique of applanation to-
nometry, which noninvasively measures PWA and PWV [10]. 
This study demonstrated that valsartan reduced central hemo-
dynamic parameters, AIx and aortic pulse pressure. These 
findings are consistent with those of previous reports that ARBs 
reduce arterial stiffness [6-8]. Central blood pressure and AIx, 
a composite measure of systemic arterial stiffness, can be as-
sessed with PWA of the radial artery waveform. The pressure 
wave can reflect the status of the peripheral vasculature, i.e., 
branching, resistance, stenosis, and return towards the heart. 
When vessels are stiffened, the returned wave may add to the 
ejection pressure. In addition, the late systolic augmentation of 
the central pressure waveform is associated with an increased 
left ventricular mass index. Therefore, an increased AIx is as-
sociated with coronary artery disease. Increased stiffness of 
the aorta and large arteries leads to an increase in the pulse 
pressure, through a reduction in arterial compliance, and a 
premature return of reflected waves in late systole, which in-
creases the load on the ventricle and the myocardial oxygen 
demand [11]. In our study, SEVR and ED were not changed 
after valsartan administration. These results could be explained 
by the results of previous studies showing that the mean aortic 
pressure and pulse pressure did not contribute to the SEVR 
and ED [12,13]. No changes were observed in glucose metab-
olism, insulin resistance or lipid profiles after valsartan admin-
istration. Valsartan reduced systolic and diastolic blood pres-
sures, but only the alteration of SBP was correlated with the 
changes in central hemodynamic parameters showing arterial 
stiffness in this study. 
  Aortic PWV is a one of the well-validated parameters of 
Table 4. The relationship between baseline parameters and 
PWV alteration after valsartan treatment 
Parameter
Univariate
analysis
Multivariate 
analysis
 a
PWV  
decrease 
(n=34 )
No PWV 
decrease 
(n=13)
P value HR P value
Age, yr 58.0±7.5 58.1±7.7 0.975
DM duration, yr 4.6±3.6 4.3±3.0 0.805
BMI, kg/m
2 25.5±2.4 25.8±2.4 0.739
Fasting blood  
glucose, mmol/L
7.7±1.9 9.1±2.2 <0.05
HbA1c, % 7.1±1.0 8.6±1.1 <0.001 2.638
 b 0.002
HOMA-IR 2.5±1.8 3.2±2.5 0.313
Total cholesterol, 
mmol/L
4.8±0.9 4.9±1.0 0.864
HDL-C, mmol/L 1.3±0.4 1.2±0.3 0.304
Triglyceride,  
mmol/L
1.8±1.1 2.1±1.4 0.472
LDL-C, mmol/L 2.7±0.7 2.8±0.8 0.441
SBP, mm Hg 148.2±5.6 147.7±7.0 0.783
DBP, mm Hg 91.8±6.4 90.8±1.9 0.214
Change in MAP,  
mm Hg
16.2±12.0 10.5±14.8 0.179
PWV, pulse wave velocity; HR, hazard ratio; DM, diabetes mellitus; 
BMI, body mass index; HbA1c, haemoglobin A1c; HOMA-IR, ho-
meostasis model assessment of insulin resistance; HDL-C, high den-
sity lipoprotein cholesterol; LDL-C, low density lipoprotein choles-
terol; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
MAP, mean arterial pressure. 
aMultivariate analysis was performed using binary logistic regression 
model with ‘Forward: LR’ method, 
bThe HR is predictive risk for ‘no 
decrease of PWV value’ in the case of an increase in the HbA1c level, 
and the accuracy rate of classification is 78.3% (95% CI, 1.447 to 
4.810). 240
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central arterial stiffness and generalized atherosclerosis [14]. 
Moreover, it is considered an independent predictor for car-
diovascular morbidity and mortality in subjects with T2DM 
[15]. In our data, aortic PWV was also reduced by valsartan 
treatment. It could be a passive effect of the reduction of mean 
arterial pressure by 12 mm Hg after valsartan treatment (data 
not shown). However, in some patients of our study, a lack of 
reduction in aortic PWV was shown in state of decline in cen-
tral blood pressure. Our results suggest that baseline glucose 
control status is associated with modulation of arterial stiffness 
by valsartan. Although one possible mechanism by which val-
sartan decreases arterial stiffness is via a decrease in blood 
pressure, ARBs modulate arterial stiffness independently of 
the brachial, central BP lowering and of the passive effect of 
pressure on arterial elastic properties [7]. Therefore, ARBs 
may act on arterial stiffness by other mechanisms. 
  Among local hormone factors associated with the modifica-
tion of the arterial wall, angiotensin II may play an important 
role through the AT1 receptor, because it induces proliferation 
of vascular smooth muscle cells and increases collagen synthe-
sis by fibroblasts [16,17]. Angiotensin II contributes to cell in-
jury, endothelial dysfunction, and vascular toxicity and fibro-
sis [18,19]. It also mediates the accumulation and activation of 
inflammatory cells, and an increase in vascular permeability, 
which results in premature vascular complications [20]. There-
fore, ARB reverses these changes in the vascular wall and may 
improve the stiffness.
  In patients with T2DM, over-activation of the RAAS occurs 
and affects cardiovascular homeostasis. Owing to the inhibi-
tion of the RAAS, ACE inhibitors and ARBs may have greater 
cardio-protective benefits in T2DM patients [21-23]. ARBs 
can reduce the negative influence of angiotensin II on the en-
dothelium, with subsequent improvement of arterial elasticity. 
Other advantageous aspects of ARBs are a reduction in oxida-
tive stress, expression of proinflammatory vascular cell adhe-
sion molecules and stimulation of adipogenesis, leading to im-
proved glucose transport [24,25]. 
  Patients with both diabetes and hypertension have higher 
arterial stiffness than those with diabetes or hypertension alone 
[26]. In patients with both diseases, angiotensin II receptor 
blockade is expected to play a more important role in protec-
tion against cardiovascular disease, by improving arterial stiff-
ness. Few previous reports regarding T2DM with hyperten-
sion have focused on the effect of ARBs on arterial stiffness and 
related parameters [7,26,27]. Our findings that valsartan sig-
nificantly reduces arterial stiffness as demonstrated be estima-
tion of PWA and PWV in T2DM patients with hypertension, 
was based on observational findings during a relatively short 
period, of 12 weeks. Moreover, baseline glucose control status 
is associated with modulation of arterial stiffness by valsartan, 
i.e., with better diabetes control, valsartan treatment will be 
more effective for treating T2DM patients with hypertension. 
A previous study analyzing the effects of T2DM with hyper-
tension on the arterial wall has reported a highly significant 
correlation between PWV and the fasting glucose level, among 
the various risk factors [26]. The mechanism by which arterial 
stiffness is increased in diabetes is largely unknown. However, 
one possible mechanism is related to changes in elastin and 
collagen within the walls. Therefore, hyperglycemia due to di-
abetes is thought to affect atherosclerosis of large arteries, and 
promote the formation of advanced glycation end-products in 
the arterial wall [26]. Advanced glycation end-products are 
believed to cause the cross-linking of collagen molecules, lead-
ing to a loss of collagen elasticity and a subsequent increase in 
arterial stiffness [28]. Chronic hyperglycaemia and hyperinsu-
linaemia also increase local RAAS activity and the expression 
of the AT1 receptor in vascular tissue, promoting development 
of wall hypertrophy and fibrosis [29]. Low-grade inflamma-
tion and endothelial dysfunction may partly explain the in-
crease in arterial stiffness related to diabetes [30]. In this re-
gard, concomitant blood glucose control and treatment with 
ARBs are expected to induce favorable cardio-protective effects 
in this population. Such treatments would be recommended in 
the early stages of diabetes and hypertension, before vascular 
modulation has progressed. 
  Our study has some limitations. First, there was no control 
group treated with another class of anti-hypertensive drug. We 
can not establish whether valsartan reduced arterial stiffness 
independently of its blood pressure lowering effect. Second, 
the failure of valsartan to improve arterial stiffness in patients 
with uncontrolled diabetes was not completely understood. 
We suggest that the vascular changes over the 12-week treat-
ment period may be insufficient to positively affect arterial 
stiffness under conditions in which glucose is uncontrolled. 
The changes in aortic PWV were supposed to be influenced by 
long term pressure-dependent vascular structure changes. The 
differential impact of ARB on aortic PWV could not be re-
flected sufficiently because of the short-term period of this 
study. Nevertheless, this study is one of very few studies, espe-
cially in Asian people, evaluating the effect of ARB on arterial 241
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stiffness and related parameters in T2DM with hypertension. 
Further investigations will elucidate the mechanism by which 
the glucose control status affects arterial stiffness after valsar-
tan treatment. 
  In conclusion, this study shows that treatment with the ARB, 
valsartan, improved arterial stiffness over a relatively short 
treatment period of 12 weeks in T2DM patients with hyper-
tension. The fasting glucose and HbA1c levels are indepen-
dently associated with PWV improvement attributable to the 
action of valsartan. Valsartan may be useful for delaying and 
reducing the influence of cardiovascular risk factors on arteri-
al stiffness in high-risk patients such as those with T2DM with 
hypertension.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
REFERENCES
1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mor-
tality from coronary heart disease in subjects with type 2 dia-
betes and in nondiabetic subjects with and without prior myo-
cardial infarction. N Engl J Med 1998;339:229-34.
2. Cockcroft JR, Webb DJ, Wilkinson IB. Arterial stiffness, hyper-
tension and diabetes mellitus. J Hum Hypertens 2000;14:377-80.
3. Lehmann ED, Gosling RG, Sonksen PH. Arterial wall compli-
ance in diabetes. Diabet Med 1992;9:114-9.
4. Dart AM, Kingwell BA. Pulse pressure: a review of mechanisms 
and clinical relevance. J Am Coll Cardiol 2001;37:975-84.
5. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen 
S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse 
wave velocity as index of arterial stiffness in the general popu-
lation. Circulation 2006;113:664-70.
6. Agata J, Nagahara D, Kinoshita S, Takagawa Y, Moniwa N, Yo-
shida D, Ura N, Shimamoto K. Angiotensin II receptor blocker 
prevents increased arterial stiffness in patients with essential 
hypertension. Circ J 2004;68:1194-8.
7. Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, 
Botha J, Ferber P, Viberti G. Valsartan improves arterial stiff-
ness in type 2 diabetes independently of blood pressure lower-
ing. Hypertension 2008;51:1617-23.
8. Okura T, Watanabe S, Kurata M, Koresawa M, Irita J, Enomoto 
D, Jotoku M, Miyoshi K, Fukuoka T, Higaki J. Long-term effects 
of angiotensin II receptor blockade with valsartan on carotid 
arterial stiffness and hemodynamic alterations in patients with 
essential hypertension. Clin Exp Hypertens 2008;30:415-22.
9. Pauca AL, O’Rourke MF, Kon ND. Prospective evaluation of a 
method for estimating ascending aortic pressure from the ra-
dial artery pressure waveform. Hypertension 2001;38:932-7.
10. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, 
Cockcroft JR, Webb DJ. Reproducibility of pulse wave velocity 
and augmentation index measured by pulse wave analysis. J 
Hypertens 1998;16(12 Pt 2):2079-84.
11. Nichols WW, O’Rourke MF. McDonald’s blood flow in arteries: 
theoretical, experimental and clinical principles. 3rd ed. Lon-
don: Lea and Febier; 1990. p77-142, 216-69, 283-359, 398-437.
12. Chemla D, Nitenberg A, Teboul JL, Richard C, Monnet X, le 
Clesiau H, Valensi P, Brahimi M. Subendocardial viability ratio 
estimated by arterial tonometry: a critical evaluation in elderly 
hypertensive patients with increased aortic stiffness. Clin Exp 
Pharmacol Physiol 2008;35:909-15.
13. Brooks BA, Molyneaux LM, Yue DK. Augmentation of central 
arterial pressure in type 2 diabetes. Diabet Med 2001;18:374-80.
14. Cohn JN, Finkelstein S, McVeigh G, Morgan D, LeMay L, Rob-
inson J, Mock J. Noninvasive pulse wave analysis for the early 
detection of vascular disease. Hypertension 1995;26:503-8.
15. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, 
Gosling RG. Aortic pulse-wave velocity and its relationship to 
mortality in diabetes and glucose intolerance: an integrated in-
dex of vascular function? Circulation 2002;106:2085-90.
16. Kim S, Iwao H. Molecular and cellular mechanisms of angio-
tensin II-mediated cardiovascular and renal diseases. Pharma-
col Rev 2000;52:11-34.
17. Williams B. Angiotensin II and the pathophysiology of cardio-
vascular remodeling. Am J Cardiol 2001;87(8A):10C-7C.
18. Johnston CI. Tissue angiotensin converting enzyme in cardiac 
and vascular hypertrophy, repair, and remodeling. Hyperten-
sion 1994;23:258-68.
19. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashi-
ra K, Imaizumi T. Hypertensive myocardial fibrosis and dia-
stolic dysfunction: another model of inflammation? Hyperten-
sion 2004;43:739-45.
20. Luft FC. Angiotensin, inflammation, hypertension, and cardio-
vascular disease. Curr Hypertens Rep 2001;3:61-7.
21. Heart Outcomes Prevention Evaluation Study Investigators. 
Effects of ramipril on cardiovascular and microvascular out-
comes in people with diabetes mellitus: results of the HOPE 
study and MICRO-HOPE substudy. Lancet 2000;355:253-9.242
Kim JH, et al.
Diabetes Metab J 2011;35:236-242 http://e-dmj.org
22. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de 
Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Ped-
ersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, We-
del H; LIFE Study Group. Cardiovascular morbidity and mor-
tality in the Losartan Intervention For Endpoint reduction in 
hypertension study (LIFE): a randomised trial against atenolol. 
Lancet 2002;359:995-1003.
23. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de 
Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Led-
erballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel 
H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Cardio-
vascular morbidity and mortality in patients with diabetes in 
the Losartan Intervention For Endpoint reduction in hyper-
tension study (LIFE): a randomised trial against atenolol. Lan-
cet 2002;359:1004-10.
24. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer 
D, Mohanty P, Tripathy D, Garg R. Angiotensin II receptor 
blocker valsartan suppresses reactive oxygen species genera-
tion in leukocytes, nuclear factor-kappa B, in mononuclear 
cells of normal subjects: evidence of an antiinflammatory ac-
tion. J Clin Endocrinol Metab 2003;88:4496-501.
25. Schling P, Loffler G. Effects of angiotensin II on adipose conver-
sion and expression of genes of the renin-angiotensin system in 
human preadipocytes. Horm Metab Res 2001;33:189-95.
26. Tedesco MA, Natale F, Di Salvo G, Caputo S, Capasso M, Cal-
abro R. Effects of coexisting hypertension and type II diabetes 
mellitus on arterial stiffness. J Hum Hypertens 2004;18:469-73.
27. Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein 
E, Katsahian S, Laloux B, Thuillez C, Struijker-Boudier H, 
Laurent S. Brachial pressure-independent reduction in carotid 
stiffness after long-term angiotensin-converting enzyme inhi-
bition in diabetic hypertensives. Hypertension 2006;48:80-6.
28. Aronson D. Cross-linking of glycated collagen in the patho-
genesis of arterial and myocardial stiffening of aging and dia-
betes. J Hypertens 2003;21:3-12.
29. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes 
and vascular disease: pathophysiology, clinical consequences, 
and medical therapy. Part I. Circulation 2003;108:1527-32.
30. Wakabayashi I, Masuda H. Association of acute-phase reac-
tants with arterial stiffness in patients with type 2 diabetes mel-
litus. Clin Chim Acta 2006;365:230-5.